Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.
A 10 mg/kg dose of ipilimumab led to significant improvement in overall survival (OS) in individuals with advanced melanoma compared with a 3 mg/kg dose, but was also associated with a higher number of treatment-related adverse events (TRAEs), according to findings of a recent study.
Individuals with untreated advanced melanoma given a combination of nivolumab and ipilimumab demonstrated greater overall survival (OS) than those on ipilimumab only, according to findings of the CheckMate 067* trial presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, US.
Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.
Growth and differentiation factor 15 (GDF-15) may be used as a marker of overall survival (OS) in some patients with melanoma, with a recent study showing that high serum levels of GDF-15 are independently associated with poorer OS in those with tumour-free stage III and those with unresectable stage IV melanoma.
Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.
Ipilimumab, given as adjuvant therapy after complete resection of stage III melanoma, significantly improved overall survival (OS) and distant metastases-free survival (DMFS) vs placebo, according to new results from the EORTC 18071 trial. [ESMO 2016, abstract LBA2_PR]
Combining ipilimumab and local peripheral treatments (LPT) such as radiotherapy or electrochemotherapy improved overall survival (OS) in individuals with advanced malignant melanoma, a recent study claims.
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from a large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.